share_log

Altimmune | 8-K: Current report

Altimmune | 8-K: Current report

Altimmune | 8-K：重大事件
美股SEC公告 ·  09/26 16:47

Moomoo AI 已提取核心訊息

On September 26, 2024, Altimmune, Inc., a biopharmaceutical company, conducted its 2024 Annual Meeting of Stockholders. At the meeting, a quorum was achieved with 61.5% of the outstanding shares represented. The stockholders voted on several key proposals, including the election of directors, ratification of Ernst & Young LLP as the independent auditor for the upcoming year, an advisory vote on executive compensation, and a vote to authorize adjournment to solicit additional proxies if necessary. The election of directors saw varying levels of support for each candidate, with Mitchel Sayare, Ph.D., and Diane Jorkasky, M.D., receiving the highest number of 'For' votes. The appointment of Ernst & Young LLP was overwhelmingly ratified, and the 'say-on-pay' proposal received more 'For' votes than 'Against', though not as decisively. The authorization to adjourn the meeting, if needed, was also approved by a significant margin. The meeting's outcomes are crucial for investors as they reflect shareholder sentiment and the strategic direction of the company.
On September 26, 2024, Altimmune, Inc., a biopharmaceutical company, conducted its 2024 Annual Meeting of Stockholders. At the meeting, a quorum was achieved with 61.5% of the outstanding shares represented. The stockholders voted on several key proposals, including the election of directors, ratification of Ernst & Young LLP as the independent auditor for the upcoming year, an advisory vote on executive compensation, and a vote to authorize adjournment to solicit additional proxies if necessary. The election of directors saw varying levels of support for each candidate, with Mitchel Sayare, Ph.D., and Diane Jorkasky, M.D., receiving the highest number of 'For' votes. The appointment of Ernst & Young LLP was overwhelmingly ratified, and the 'say-on-pay' proposal received more 'For' votes than 'Against', though not as decisively. The authorization to adjourn the meeting, if needed, was also approved by a significant margin. The meeting's outcomes are crucial for investors as they reflect shareholder sentiment and the strategic direction of the company.
2024年9月26日，生物製藥公司Altimmune, Inc.召開了2024年股東年度大會。在會議上，獲得了61.5%的優先股持有者代表了出席的法定人數。股東投票表決了幾項關鍵提案，包括選舉董事，審議Ernst & Young LLP作爲未來一年的獨立核數師，對高管薪酬的諮詢投票，以及授權推遲會議以徵求必要的額外委託人。選舉董事看到每位候選人的支持度有所不同，Mitchel Sayare博士和Diane Jorkasky女士獲得了最多的『贊成』票。對Ernst & Young LLP的任命得到了壓倒性的批准，而『薪酬表決』提案獲得了比『反對』更多的『贊成』票，儘管支持度沒有那麼決定性。如有需要，推遲會議的授權也得到了明顯多數的批准。會議的結果對投資者至關重要，因爲它們反映了股東的情緒和公司戰略方向。
2024年9月26日，生物製藥公司Altimmune, Inc.召開了2024年股東年度大會。在會議上，獲得了61.5%的優先股持有者代表了出席的法定人數。股東投票表決了幾項關鍵提案，包括選舉董事，審議Ernst & Young LLP作爲未來一年的獨立核數師，對高管薪酬的諮詢投票，以及授權推遲會議以徵求必要的額外委託人。選舉董事看到每位候選人的支持度有所不同，Mitchel Sayare博士和Diane Jorkasky女士獲得了最多的『贊成』票。對Ernst & Young LLP的任命得到了壓倒性的批准，而『薪酬表決』提案獲得了比『反對』更多的『贊成』票，儘管支持度沒有那麼決定性。如有需要，推遲會議的授權也得到了明顯多數的批准。會議的結果對投資者至關重要，因爲它們反映了股東的情緒和公司戰略方向。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間